Dataset of EGFRm NSCLC patients’ mutation profiles at resistance to osimertinib as 1st-line or 2nd-line treatment according to NGS based liquid biopsy tests.

Published: 23 November 2020| Version 1 | DOI: 10.17632/dhb59kkshk.1
Vered Fuchs


In an approach to deepen the understanding and clarify possible mechanisms of osimertinib 1st-line resistance in comparison to the 2nd line we have examined NGS results of 30 patients who developed resistance to osimertinib. Liquid biopsy technique (Guardant360) was used to monitor tumor dynamics in patients who were treated with osimertinib as 1st-line therapy (Group A, N=15) and patients who received osimertinib as 2nd-line therapy (Group B, N=15). The raw data are composed of two tables presenting information of advanced EGFR mutated NSCLC patients who received treatment with osimertinib as 1st-line or 2nd-line therapy after developing resistance to early generation TKIs. Table 1 comprises data of 15 patients who received osimertinib as 1st-line and describes the patients’ gender, age at diagnosis, initial EGFR mutation (exon 19 deletion, L858R, or uncommon sensitizing EGFR mutations), initial other mutations found (if available), progression free survival (PFS) on osimertinib treatment and mutations at resistance to osimertinib detected by NGS liquid biopsy tests. Table 2 comprises data of 15 patients who received osimertinib as 2nd-line, previously treated with 1st/2nd-generation EGFR TKIs in whom p.T790M was diagnosed either in the tumor specimen or in the circulating tumor DNA (ctDNA) after testing it following the most recent disease progression. Table 2 includes the parameters described in table 1 in addition to first line TKI treatment (gefitinib, erlotinib, or afatinib) and PFS after 1st line TKI treatment.



Lung Cancer, Non-Small Cell Lung Cancer, Osimertinib, Mechanism of Resistance, Tyrosine Kinase Inhibitor